Drugs / Ivermectin
Ivermectin
also known as
IVM · CD5024 · Mectizan · Stromectol · CHILD-IVITAB · Driponin · IVER · IVER P · +7 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | SKLICE | — | 2020-10-27 | fda.gov ↗ |
| Approved | US (FDA) | STROMECTOL | — | 1996-11-22 | fda.gov ↗ |
Trials 154 · started per year
today
US approved 1996
1
2
2
1
1
1
3
4
3
2
2
7
5
12
7
8
5
34
26
10
6
1
7
3
1
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07396714 | Feb 2026 → Feb 2027 expected | skin disorder caused by infection | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07286604 | Mar → Jun 2022 | cutaneous leishmaniasis | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 0 | NCT04108897 | Sep 2019 → Sep 2027 expected | rosacea | Johns Hopkins University | Active not recruiting | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT07795567 | Dec 2025 → Jun 2026 | rosacea | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04482686 | Dec 2020 → May 2022 | COVID-19 | ProgenaBiome | Completed | No outcome recorded |
| Phase 1 | NCT04632706 | Sep 2020 → Mar 2021 | COVID-19 | MedinCell S.A | Completed | No outcome recorded |
| Phase 1 | NCT04343092 | Apr → May 2020 | COVID-19 | University of Baghdad | Completed | No outcome recorded |
| Phase 1 | NCT03717558 | Apr 2018 | — | Pierre Fabre Dermatology | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02963324 | Nov → Dec 2016 | malaria | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT03173742 | Mar → Dec 2016 | helminthiasis | Insud Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02568098 | Oct 2015 → Dec 2016 | — | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT00988533 | Sep → Nov 2009 | Pediculus humanus capitis infestation | Topaz Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT05318469 | Oct 2023 → Oct 2026 expected | triple-negative breast carcinoma | Yuan Yuan | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04701710 | Oct → Dec 2020 | COVID-19, severe acute respiratory syndrome | Maria de los Angeles Peral de Bruno | Completed | No outcome recorded |
| Phase 1/2 | NCT04784481 | Sep → Dec 2020 | COVID-19, severe acute respiratory syndrome | Ministry of Public Health, Argentina | Completed | No outcome recorded |
| Phase 1/2 | NCT04591600 | Jul → Sep 2020 | COVID-19 | Alkarkh Health Directorate-Baghdad | Completed | No outcome recorded |
| Phase 1/2 | NCT02806414 | Jul 2016 → Jul 2019 | rosacea | University of California, San Diego | Completed | No outcome recorded |
| Phase 1/2 | NCT02046200 | Feb 2014 → Mar 2015 | alcohol-related disorders | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1/2 | NCT01603251 | Jan → Apr 2013 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 237 trials · 4 met primary · 5 missed | ||||||
| Phase 2 | NCT03553615 | Dec 2030 | atopic eczema | Stanford University | Withdrawn | No outcome recorded |
| Phase 2 | NCT07487805 | Sep 2026 → Sep 2027 expected | cancer | University of Florida | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07045493 | Jul 2025 → Mar 2026 overdue | intestinal helminthiasis | International Centre for Diarrhoeal Disease Research, Bangladesh | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05500326 | Jun 2025 → Jun 2026 overdue | scabies | Murdoch Childrens Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07710638 | Jun 2025 → Jul 2026 | common wart | Al-Azhar University | Completed | No outcome recorded |
| Phase 2 | NCT06896929 | May 2025 → Apr 2026 overdue | scabies | Children Hospital and Institute of Child Health, Lahore | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06404333 | Feb → Nov 2025 | scabies | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT06373835 | May → Sep 2024 | strongyloidiasis | Swiss Tropical & Public Health Institute | Completed | No outcome recorded |
| Phase 2 | NCT04332068 | Nov 2023 → Apr 2025 | scabies | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT06033352 | Sep 2023 → Nov 2024 | rosacea | Insel Gruppe AG, University Hospital Bern | Completed | Met primary |
| Phase 2 | NCT05269030 | Jul 2022 → Mar 2023 | — | Menoufia University | Unknown | No outcome recorded |
| Phase 2 | NCT05305560 | Mar → Sep 2022 | COVID-19 | MedinCell S.A | Completed | No outcome recorded |
| Phase 2 | NCT05155527 | Feb → Jun 2022 | COVID-19 | Mahidol University | Unknown | No outcome recorded |
| Phase 2 | NCT05041907 | Sep 2021 → Jan 2027 expected | COVID-19 | University of Oxford | Recruiting | Mixed |
| Phase 2 | NCT04836299 | May → Jul 2021 | COVID-19 | Universidad Mayor de San Simón | Unknown | No outcome recorded |
| Phase 2 | NCT04602507 | Dec 2020 → Dec 2021 | COVID-19, severe acute respiratory syndrome | CES University | Terminated | No outcome recorded |
| Phase 2 | NCT04703205 | Sep 2020 → Oct 2021 | COVID-19 | Kitasato University | Unknown | Missed primary |
| Phase 2 | NCT04510233 | Sep → Oct 2020 | COVID-19 | Tanta University | Unknown | No outcome recorded |
| Phase 2 | NCT04438850 | Jul 2020 → Jun 2021 | COVID-19 | IRCCS Sacro Cuore Don Calabria di Negrar | Terminated | No outcome recorded |
| Phase 2 | NCT04447235 | Jul 2020 → Jun 2022 | COVID-19, cancer | Cancer Institute of the State of São Paulo | Terminated | No outcome recorded |
| Phase 2 | NCT04407507 | Jul 2020 → Jan 2021 | COVID-19 | Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. | Completed | Missed primary |
| Phase 2 | NCT04431466 | Jul → Dec 2020 | COVID-19 | Universidade Federal de Sao Carlos | Terminated | No outcome recorded |
| Phase 2 | NCT04381884 | May → Sep 2020 | — | Laboratorio Elea Phoenix S.A. | Completed | Missed primary |
| Phase 2 | NCT04374019 | May → Dec 2020 | COVID-19 | Susanne Arnold | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04041453 | Oct 2019 → Mar 2020 | trichuriasis | Alejandro Krolewiecki | Completed | No outcome recorded |
| Phase 2 | NCT03432442 | Sep 2018 → Sep 2020 | Dengue hemorrhagic fever | Mahidol University | Completed | No outcome recorded |
| Phase 2 | NCT03664063 | Sep → Oct 2018 | filariasis, yaws | Lihir Medical Centre | Completed | Met primary |
| Phase 2 | NCT03286101 | Sep → Oct 2017 | Pediculus humanus capitis infestation | United Laboratories | Completed | No outcome recorded |
| Phase 2 | NCT03250624 | Nov 2016 → Jun 2017 | atopic eczema | Galderma R&D | Completed | Missed primary |
| Phase 2 | NCT03034460 | Apr → Nov 2016 | acne | Galderma R&D | Completed | Missed primary |
| Phase 2 | NCT02511353 | Jul 2015 → Jul 2016 | malaria | Liverpool School of Tropical Medicine | Completed | Met primary |
| Phase 2 | NCT01975441 | May 2014 → Dec 2017 | filariasis | University Hospitals Cleveland Medical Center | Completed | Met primary |
| Phase 2 | NCT02366884 | Jul 2011 → Dec 2022 | neoplasm | Dr. Frank Arguello Cancer Clinic | Unknown | No outcome recorded |
| Phase 2 | NCT00994422 | Oct → Dec 2009 | Pediculus humanus capitis infestation | Topaz Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 2 | NCT00857948 | Mar → Apr 2009 | Pediculus humanus capitis infestation | Topaz Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 2 | NCT00339417 | Feb 2006 → Aug 2008 | filariasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00262418 | Jul 2004 → May 2005 | scabies | University Ghent | Completed | No outcome recorded |
| Phase 2/316 trials · 2 met primary · 1 missed | ||||||
| Phase 2/3 | NCT05283954 | May → Jun 2022 | COVID-19 | Oriol Mitja | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT05124691 | Jan 2022 → Mar 2023 | intestinal helminthiasis | Barcelona Institute for Global Health | Terminated | Met primary |
| Phase 2/3 | NCT04886362 | Jul → Sep 2021 | pneumonia | Ayudas Diagnosticas Sura S.A.S | Unknown | No outcome recorded |
| Phase 2/3 | NCT04894721 | Jun → Sep 2021 | COVID-19 | Ministry of Public Health, Argentina | Completed | No outcome recorded |
| Phase 2/3 | NCT04959786 | Apr 2021 → Nov 2022 | pneumonia | Mansoura University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04768179 | Feb → Jun 2021 | COVID-19 | Makerere University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04716569 | Jan → Feb 2021 | COVID-19 | South Valley University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04405843 | Jul → Dec 2020 | COVID-19 | Centro de Estudios en Infectogía Pediatrica | Completed | Missed primary |
| Phase 2/3 | NCT04351347 | Jun 2020 → Dec 2030 expected | COVID-19 | Tanta University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04403555 | Jun → Oct 2020 | COVID-19 | Tanta University | Completed | No outcome recorded |
| Phase 2/3 | NCT04422561 | May → Jul 2020 | COVID-19 | Zagazig University | Completed | No outcome recorded |
| Phase 2/3 | NCT04445311 | May → Jul 2020 | COVID-19 | Zagazig University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04360356 | May → Oct 2020 | COVID-19 | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03527732 | Sep 2018 → May 2020 | trichuriasis | Jennifer Keiser | Completed | Mixed |
| Phase 2/3 | NCT02509481 | Jun → Nov 2015 | filariasis, malaria | Colorado State University | Completed | Met primary |
| Phase 2/3 | NCT02045069 | Feb 2014 → Feb 2016 | dengue disease | Mahidol University | Unknown | No outcome recorded |
| Phase 349 trials · 9 met primary · 11 missed | ||||||
| Phase 3 | NCT06282315 | Sep 2025 → Apr 2026 overdue | intestinal helminthiasis | Insud Pharma | Recruiting | No outcome recorded |
| Phase 3 | NCT06037876 | Oct → Nov 2023 | trichuriasis | Jennifer Keiser | Completed | Met primary |
| Phase 3 | NCT05946642 | Jul 2023 → May 2024 | malaria | Malaria Consortium | Unknown | No outcome recorded |
| Phase 3 | NCT04966702 | Mar 2022 → Apr 2024 | malaria | Barcelona Institute for Global Health | Completed | Mixed |
| Phase 3 | NCT05894538 | Feb → Aug 2022 | COVID-19 | Susanna Naggie, MD | Completed | Missed primary |
| Phase 3 | NCT04848688 | Feb → Jul 2022 | strongyloidiasis | Jennifer Keiser | Completed | Met primary |
| Phase 3 | NCT05060666 | Nov 2021 → Mar 2022 | COVID-19 | Infectopharm Arzneimittel GmbH | Unknown | No outcome recorded |
| Phase 3 | NCT05056883 | Oct 2021 → Aug 2022 | COVID-19 | Kowa Company, Ltd. | Completed | Missed primary |
| Phase 3 | NCT04937569 | Jul → Sep 2021 | COVID-19 | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT04726969 | Jun → Sep 2021 | ascariasis, hookworm infectious disease, trichuriasis | Jennifer Keiser | Completed | Missed primary |
| Phase 3 | NCT04814511 | Jun 2021 → Dec 2022 | scabies | Infectopharm Arzneimittel GmbH | Unknown | No outcome recorded |
| Phase 3 | NCT04885530 | Jun 2021 → Apr 2024 | COVID-19 | Susanna Naggie, MD | Completed | No outcome recorded |
| Phase 3 | NCT05736861 | Jun 2021 → Mar 2022 | COVID-19 | Susanna Naggie, MD | Completed | No outcome recorded |
| Phase 3 | NCT04920942 | May → Oct 2021 | COVID-19 | Clinical Research Centre, Malaysia | Completed | Missed primary |
| Phase 3 | NCT05040724 | May 2021 → May 2022 | — | Raincy Montfermeil Hospital Group | Unknown | No outcome recorded |
| Phase 3 | NCT04844905 | May 2021 → Mar 2023 | Plasmodium falciparum malaria, filariasis, hookworm infectious disease, scabies +1 | London School of Hygiene and Tropical Medicine | Unknown | Missed primary |
| Phase 3 | NCT03876262 | May 2021 → Jul 2024 overdue | onchocerciasis | Medicines Development for Global Health | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04530474 | Apr → Jun 2021 | COVID-19 | Temple University | Withdrawn | No outcome recorded |
| Phase 3 | NCT04703608 | Jan 2021 → Mar 2022 | COVID-19 | London School of Hygiene and Tropical Medicine | Unknown | No outcome recorded |
| Phase 3 | NCT05993143 | Jan → Jul 2021 | COVID-19 | Insud Pharma | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04510194 | Jan 2021 → Dec 2022 | COVID-19 | University of Minnesota | Completed | Missed primary |
| Phase 3 | NCT04673214 | Dec 2020 → Feb 2021 | COVID-19 | Gilberto Cruz Arteaga | Completed | Missed primary |
| Phase 3 | NCT04834115 | Nov 2020 → Apr 2021 | COVID-19 | Universidad Nacional de Asunción | Unknown | No outcome recorded |
| Phase 3 | NCT04527211 | Sep → Nov 2020 | COVID-19 | Javeriana University | Unknown | No outcome recorded |
| Phase 3 | NCT04446104 | May → Aug 2020 | COVID-19 | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 3 | NCT04646109 | May → Sep 2020 | COVID-19 | Afyonkarahisar Health Sciences University | Completed | Missed primary |
| Phase 3 | NCT04391127 | May → Nov 2020 | COVID-19 | Centenario Hospital Miguel Hidalgo | Completed | No outcome recorded |
| Phase 3 | NCT03967054 | Jul 2019 → Nov 2020 | malaria | Brian Foy | Completed | Missed primary |
| Phase 3 | NCT03576313 | Aug 2018 → Dec 2019 | malaria | London School of Hygiene and Tropical Medicine | Completed | Mixed |
| Phase 3 | NCT06259383 | Jan 2018 → Dec 2021 | — | Prince of Songkla University | Completed | No outcome recorded |
| Phase 3 | NCT03301649 | Oct 2017 → Mar 2018 | Pediculus humanus capitis infestation | Actavis Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03236168 | Aug → Dec 2017 | Pediculus humanus capitis infestation, scabies | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03074435 | Jul 2016 → Aug 2018 | malaria | Research Institute for Development | Completed | Met primary |
| Phase 3 | NCT02840461 | Jun → Nov 2016 | rosacea | Actavis Inc. | Completed | Met primary |
| Phase 3 | NCT02795117 | May 2016 → Feb 2017 | rosacea | Padagis LLC | Completed | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT02407782 | Jan 2016 → Dec 2021 | scabies | University Hospital, Bordeaux | Completed | Missed primary |
| Phase 3 | NCT02236403 | Oct 2014 → Jan 2015 | blepharitis | National University of Colombia | Completed | No outcome recorded |
| Phase 3 | NCT02078024 | Jun 2014 → Jun 2018 | onchocerciasis | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02036229 | Feb 2014 → Dec 2015 | demodicidosis, rosacea | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01570504 | Mar 2013 → Jun 2018 | strongyloidiasis | Centro per le Malattie Tropicali | Completed | Missed primary |
| Phase 3 | NCT01493947 | Apr 2012 → Dec 2013 | rosacea | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT03238131 | Apr 2012 → Apr 2015 | onchocerciasis | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01494467 | Dec 2011 → Aug 2013 | rosacea | Galderma R&D | Completed | Met primary |
| Phase 3 | NCT01493687 | Dec 2011 → Jul 2013 | rosacea | Galderma R&D | Completed | Met primary |
| Phase 3 | NCT01068158 | Mar → Jun 2010 | Pediculus humanus capitis infestation | Topaz Pharmaceuticals Inc | Completed | Met primary |
| Phase 3 | NCT01066585 | Mar → Jun 2010 | Pediculus humanus capitis infestation | Topaz Pharmaceuticals Inc | Completed | Met primary |
| Phase 3 | NCT00765024 | Jul 2008 → Apr 2010 | strongyloidiasis | Mahidol University | Completed | No outcome recorded |
| Phase 3 | NCT00819520 | Feb → Sep 2004 | lice infestation | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | Met primary |
| Phase 417 trials · 1 met primary | ||||||
| Phase 4 | NCT07657143 | Jul → Nov 2026 expected | — | London School of Hygiene and Tropical Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06332872 | Dec 2023 → Mar 2024 | Pediculus humanus capitis infestation, ivermectin toxicity | Phramongkutklao College of Medicine and Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05605925 | Aug → Dec 2022 | malaria | Makerere University | Unknown | No outcome recorded |
| Phase 4 | NCT03570814 | Dec 2021 → Feb 2022 | filariasis, trachoma | London School of Hygiene and Tropical Medicine | Completed | Met primary |
| Phase 4 | NCT04891250 | Oct → Dec 2021 | COVID-19 | Centre for Infectious Disease Research in Zambia | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT05085665 | Jul → Aug 2021 | loiasis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT04944082 | Jul → Dec 2021 | COVID-19 | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT04746365 | Dec 2020 → Jan 2021 | COVID-19 | Elaraby Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04435587 | Jul 2020 → Jun 2021 | COVID-19 | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT04739410 | May → Jun 2020 | COVID-19 | FMH College of Medicine and Dentistry | Completed | No outcome recorded |
| Phase 4 | NCT03690453 | Feb 2019 → Apr 2022 | — | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT03852303 | Oct 2017 → Mar 2019 | epilepsy | University of Antwerp | Completed | No outcome recorded |
| Phase 4 | NCT03036059 | May 2017 → Dec 2019 | filariasis | Noguchi Memorial Institute for Medical Research | Completed | No outcome recorded |
| Phase 4 | NCT02775617 | Jul 2016 → Aug 2017 | impetigo, scabies, yaws | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02616250 | Dec 2015 → Sep 2016 | rosacea | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT01903057 | Feb → Mar 2014 | filariasis, trachoma | Emory University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02784743 | May 2001 → Dec 2008 | filariasis | Centre d'Appui à la lutte contre la Maladie | Completed | No outcome recorded |
| Phase not applicable16 trials · 1 missed | ||||||
| — | NCT04425707 | Jun → Jul 2020 | COVID-19 | Ministry of Health and Population, Egypt | Unknown | No outcome recorded |
| — | NCT04668469 | Jun → Sep 2020 | COVID-19 | Benha University | Completed | No outcome recorded |
| — | NCT04373824 | Apr → Jul 2020 | COVID-19 | Max Healthcare Insititute Limited | Unknown | No outcome recorded |
| — | NCT04399746 | Mar → May 2020 | COVID-19 | Institute for Social Security and Services for State Workers | Completed | No outcome recorded |
| — | NCT03598842 | Jul 2019 → Dec 2025 | helminthiasis, protein-energy malnutrition, tuberculosis | Boston Medical Center | Completed | No outcome recorded |
| — | NCT03517462 | Aug 2018 → Aug 2019 | onchocerciasis | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT03578679 | Jul 2018 → Jan 2019 | Pediculus humanus capitis infestation | Research Institute for Development | Completed | No outcome recorded |
| — | NCT03177993 | Jul → Nov 2017 | Nematoda infectious disease, filariasis, impetigo, scabies | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT05749653 | Mar 2017 → Mar 2021 | epilepsy, onchocerciasis | University of Antwerp | Completed | No outcome recorded |
| — | NCT02899936 | Jul 2016 → Apr 2017 | filariasis | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT02974049 | Jan 2015 → Sep 2018 | filariasis | University Hospitals Cleveland Medical Center | Completed | Missed primary |
| — | NCT01308268 | Dec 2010 → Apr 2012 | strongyloidiasis | Universidad Nacional de Salta | Unknown | No outcome recorded |
| — | NCT01586169 | Feb 2010 | bacterial infectious disease, parasitic infectious disease | Centre d'Appui à la lutte contre la Maladie | Completed | No outcome recorded |
| — | NCT00604084 | May 2007 → May 2008 | scabies | Edward Via Virginia College of Osteopathic Medicine | Completed | No outcome recorded |
| — | NCT00215280 | Nov 2005 → Feb 2006 | lymphedema, mansonelliasis | DBL -Institute for Health Research and Development | Completed | No outcome recorded |
| — | NCT00207753 | Feb → Mar 2005 | ascariasis, hookworm infectious disease, lice infestation, strongyloidiasis +1 | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Comparator or background therapy55 trials | ||||||
| Phase 0 | NCT06251739 Comparator | Oct 2023 → Jan 2024 | cutaneous leishmaniasis | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 0 | NCT03459794 Comparator | Feb → Apr 2018 | — | University of Georgia | Completed | No outcome recorded |
| Phase 1 | NCT05643820 Comparator | Mar → Aug 2022 | lice infestation | Combined Military Hospital Abbottabad | Completed | No outcome recorded |
| Phase 1 | NCT05362513 Comparator | Jun → Nov 2021 | scabies | Combined Military Hospital Abbottabad | Completed | No outcome recorded |
| Phase 1 | NCT02845713 Comparator | Apr → Jun 2016 | filariasis | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT05076253 Comparator | Sep → Dec 2021 | COVID-19, ivermectin toxicity | Bangkok Metropolitan Administration Medical College and Vajira Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT04472585 Comparator | Nov 2020 → Aug 2021 | COVID-19 | Sohaib Ashraf | Unknown | No outcome recorded |
| Phase 2 | NCT06184399 Comparator | Jun → Aug 2024 | ascariasis, hookworm infectious disease, trichuriasis | Jennifer Keiser | Completed | No outcome recorded |
| Phase 2 | NCT06070116 Comparator | Apr 2024 → Sep 2026 overdue | ocular onchocerciasis | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04049851 Comparator | Apr 2022 → Jul 2023 | loiasis, ocular onchocerciasis | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | Completed | No outcome recorded |
| Phase 2 | NCT05180461 Comparator | Aug 2021 → Sep 2026 overdue | onchocerciasis | Drugs for Neglected Diseases | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04275999 Background | Apr 2021 → Jan 2024 | rosacea | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04551755 Comparator | Sep → Nov 2020 | COVID-19 | Bangladesh Medical Research Council (BMRC) | Unknown | No outcome recorded |
| Phase 2 | NCT04635943 Comparator | Aug 2020 → Apr 2021 | COVID-19 | Universidad Peruana Cayetano Heredia | Completed | No outcome recorded |
| Phase 2 | NCT04390022 Comparator | Jul → Sep 2020 | COVID-19 | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
| Phase 2 | NCT04407130 Comparator | Jun → Oct 2020 | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 2 | NCT04188301 Comparator | Dec 2019 → Mar 2022 | onchocerciasis | Washington University School of Medicine | Completed | Mixed |
| Phase 2 | NCT00300768 Comparator | Sep 2006 → Nov 2009 | onchocerciasis | Medicines Development for Global Health | Completed | No outcome recorded |
| Phase 2/3 | NCT04951362 Comparator | Apr 2021 → May 2022 | anosmia | South Valley University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04700423 Comparator | Mar → Aug 2021 | ascariasis, hookworm infectious disease, intestinal helminthiasis, trichuriasis | Jennifer Keiser | Completed | Missed primary |
| Phase 2/3 | NCT04712279 Comparator | Jan → Mar 2021 | COVID-19 | Corpometria Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT04529525 Comparator | Aug 2020 → Feb 2021 | COVID-19 | Corrientes Institute of Cardiology | Completed | No outcome recorded |
| Phase 2/3 | NCT04056325 Comparator | Nov 2019 → Apr 2021 | strongyloidiasis | Jennifer Keiser | Completed | No outcome recorded |
| Phase 3 | NCT07661316 Comparator | Nov 2026 → Feb 2027 expected | ascariasis, hookworm infectious disease, strongyloidiasis, trichuriasis | Mundo Sano Foundation | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07159373 Comparator | Sep 2026 → Jun 2027 expected | filariasis, scabies, strongyloidiasis | Medicines Development for Global Health | Recruiting | No outcome recorded |
| Phase 3 | NCT05231603 Comparator | Feb → May 2022 | COVID-19 | Clinical Research Centre, Malaysia | Terminated | No outcome recorded |
| Phase 3 | NCT05213585 Comparator | Aug 2021 → Dec 2023 | — | Helm Vision Group | Completed | No outcome recorded |
| Phase 3 | NCT04311671 Comparator | May 2021 → Sep 2024 | onchocerciasis | Medicines Development for Global Health | Completed | No outcome recorded |
| Phase 3 | NCT04681053 Comparator | Feb → Apr 2021 | COVID-19 | Mansoura University | Unknown | No outcome recorded |
| Phase 3 | NCT04392427 Comparator | Oct 2020 → May 2022 | COVID-19 | Mansoura University | Unknown | No outcome recorded |
| Phase 3 | NCT04410406 Comparator | Aug 2020 → Oct 2024 | filariasis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT04523831 Comparator | Jun → Aug 2020 | COVID-19 | Dhaka Medical College | Completed | No outcome recorded |
| Phase 3 | NCT03676140 Background | Oct → Dec 2018 | filariasis, scabies, strongyloidiasis, trachoma +1 | Lihir Medical Centre | Completed | No outcome recorded |
| Phase 3 | NCT02841215 Comparator | Oct 2017 → Jan 2022 | scabies | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT03605758 Comparator | May 2012 → Feb 2015 | strongyloidiasis | Albert Einstein College of Medicine | Terminated | No outcome recorded |
| Phase 3 | NCT00790998 Comparator | Apr 2009 → Feb 2012 | onchocerciasis | Medicines Development for Global Health | Completed | Met primary |
| Phase 4 | NCT07145736 Comparator | Aug 2025 → Mar 2029 expected | ascariasis, hookworm infectious disease, onchocerciasis, scabies +1 | Kirby Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT05819983 Comparator | Jan → Feb 2023 | scabies | Padjadjaran University | Completed | No outcome recorded |
| Phase 4 | NCT05246072 Comparator | Nov 2021 → Feb 2022 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04729140 Comparator | Dec 2020 → Dec 2021 | COVID-19 | Max Health, Subsero Health | Unknown | No outcome recorded |
| Phase 4 | NCT04779047 Comparator | Oct 2020 → Mar 2021 | COVID-19, pneumonia | October 6 University | Unknown | No outcome recorded |
| Phase 4 | NCT03052998 Comparator | Oct → Dec 2017 | epilepsy, onchocerciasis | University of Antwerp | Completed | No outcome recorded |
| Phase 4 | NCT03075891 Background | Jul 2017 → Feb 2018 | rosacea | Galderma R&D | Completed | Met primary |
| Phase 4 | NCT01593722 Comparator | Apr 2012 → Aug 2013 | loiasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT07707817 Background | Jul 2026 → Jul 2027 expected | intestinal helminthiasis, onchocerciasis, schistosomiasis | Uwemedimo Friday Ekpo | Recruiting | No outcome recorded |
| — | NCT06265870 Comparator | May 2024 → Dec 2025 overdue | eosinophil disorder | Prince of Songkla University | Recruiting | No outcome recorded |
| — | NCT05930002 Comparator | Jul 2021 → Sep 2022 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| — | NCT04384458 Comparator | Jul → Sep 2020 | COVID-19 | Drug Research and Development Center, Federal University of Ceara | Unknown | No outcome recorded |
| — | NCT04429711 Comparator | May → Sep 2020 | COVID-19 | Sheba Medical Center | Unknown | No outcome recorded |
| — | NCT04392713 Comparator | Apr → Jul 2020 | COVID-19 | Combined Military Hospital, Pakistan | Unknown | No outcome recorded |
| — | NCT05198947 Comparator | Jan → Dec 2017 | scabies | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| — | NCT01213576 Comparator | Jan 2009 → Feb 2012 | filariasis | London School of Hygiene and Tropical Medicine | Terminated | No outcome recorded |
| — | NCT00817713 Comparator | Jan 2009 → Sep 2010 | HIV infectious disease, helminthiasis | Swiss Tropical & Public Health Institute | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01050517 Comparator | Oct → Dec 2007 | parasitic infectious disease | DBL -Institute for Health Research and Development | Completed | No outcome recorded |
| — | NCT01050452 Comparator | Oct 2007 → Aug 2009 | parasitic infectious disease | DBL -Institute for Health Research and Development | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-02-28 | Zydus Lifesciences Limited | Regulatory Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg zyduslife.com ↗
Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg |
| 2023-06-28 | Galderma R&D | Results WCD 2023: Galderma’s scientific presentations galderma.com ↗
Rosacea-tailored skincare routine integrated with ivermectin 1% cream and doxycycline 40mg or placebo provides benefits for patients with severe rosacea |
| 2022-12-21 | Medicines Development for Global Health | Results American Society of Tropical Medicine and Hygiene Annual Meeting medicinesdevelopment.com ↗
They also note that moxidectin plus albendazole efficacy at 12 months is similar to ivermectin plus albendazole and diethylcarbamazine (IDA) and moxidectin plus albendazole and diethylcarbamazine (MoxDA) combinations. |
| 2021-04-19 | MedinCell S.A | Results Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin medincell.com ↗
After completion, the study confirms the safety of ivermectin up to a dose of 100 µg / kg / day in continuous administration over 1 month in healthy volunteers. |
| 2020-12-17 | MedinCell S.A | Results Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin medincell.com ↗
The preliminary results of the study are presented at the “Collaborative Workshop – Ivermectin against Covid-19” held by MedinCell on December 15, 16 and 17 to foster international collaboration and speed ongoing research activities. |
| 2019-03-01 | Galderma R&D | Results Galderma: New data reveals benefits of combining oral and topical treatment in patients with severe papulopustular rosacea galderma.com ↗
Today, Galderma shares the results of its ANSWER study, which highlights a superior reduction of inflammatory lesions with combination doxycycline 40 mg modified release capsules (DMR) and ivermectin 1% cream (IVM), compared to IVM plus placebo, in adults with severe papulopustular rosacea (IGA 4*) at 12 weeks. |
| 2018-02-19 | Medicines Development for Global Health | Results Moxidectin phase III study Lancet publication medicinesdevelopment.com ↗
Moxidectin would therefore be expected to reduce parasite transmission between treatment rounds more than ivermectin could, thus accelerating progress towards elimination |
| 2015-12-10 | Medicines Development for Global Health | Results Mass drug administration for scabies control medicinesdevelopment.com ↗
The elegantly conducted randomised study, undertaken in Fijian island communities, demonstrated that oral ivermectin MDA was superior to permethrin cream MDA in reducing the prevalence of scabies infection. |
| 2015-08-13 | Medicines Development for Global Health | Regulatory TGA approves registration of Ivermectin medicinesdevelopment.com ↗
Based on a review of quality, safety and efficacy, the TGA approved the registration of ivermectin for the treatment of scabies. |
All press releases naming this drug 19 releases
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 214 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ivermectin | “We therefore propose, to explore the clinical use of combination anticoagulant: lower dose aspirin and the FDA-approved anti-parasitic drug: ivermectin, in treatment of...” NCT04768179 ↗204“World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected...” NCT06037876 ↗ “Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic...” NCT03598842 ↗ “Ivermectin is the only recommended single-dose treatment option available, but concerns of drug resistance are rightly founded, therefore driving the demand for efficacious...” PMID 40580974 ↗ Jun 2025 “Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects” NCT02568098 ↗ “Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA).” NCT03177993 ↗ “fixed dose combination (FDC) of albendazole (ALB) and ivermectin (IVM) as a single dose to treat Soil-Transmitted Helminths (STH)” NCT06282315 ↗ “Driponin 3 mg Tabletten are approved for the treatment of scabies, containing ivermectin as the active ingredient.” NCT04814511 ↗ “Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole” NCT02366884 ↗ “Ivermectin (IVM) and albendazole (ALB) are administered in areas where onchocerciasis is co-endemic;” NCT02899936 ↗ “Ivermectin is an antiparasitic drug administered to hundreds of millions of people worldwide.” PMID 38154616 ↗ Dec 2023 |
| Known as | CD5024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01493687 ↗ |
| Known as | CHILD-IVITAB | “pediatric ivermectin (CHILD-IVITAB)” NCT06404333 ↗ |
| Known as | Driponin | “IMP: Driponin® is an approved drug with the active ingredient Ivermectin, used to treat parasitic infections.” NCT05060666 ↗ |
| Known as | IVER | “combination of two pharmaceutical drugs, Azithromycin (AZIT) and Ivermectin (IVER) administered orally in the treatment of head lice infestations.” NCT03578679 ↗ |
| Known as | IVER P | “Patients in this group will receive Ivermectin (IVER P®) 600 µg / kg / once daily plus standard care.” NCT04381884 ↗ |
| Known as | IVERA | “200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose” NCT04407130 ↗ |
| Known as | Ivermectin 9 mg cp by Chemo group | “Ivermectin 9 mg cp by Chemo group” NCT04438850 ↗ |
| Known as | Ivermentin | “Ivermectin (NT007) 3 mg tablets are round, white, and scored on one side. Ivermentin 3mg tablets will be crushed and mixed thoroughly in 10mL of water.” NCT04332068 ↗ |
| Known as | IVM | “This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB...” NCT01050452 ↗19“Ivermectin (IVM) will be available as 3 mg or 6 mg tablets to be administered at the doses of 300- 400μg/kg/day for 3 days (to the nearest whole tablet). IVM should also be...” NCT05946642 ↗ “Ivermectin (IVM) is an FDA-approved antiparasitic medication that can significantly reduce alcohol intake in mice, suggesting that it may be useful in the treatment of AUDs in humans.” NCT02046200 ↗ “Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects” NCT02568098 ↗ “Severe adverse reactions have occurred after ivermectin (IVM), also a macrocyclic lactone, in individuals with high Loa microfilarial density (MFD).” PMID 38966851 ↗ Apr 2024 “Repurposing Ivermectin (IVM) for Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL): Safety and Response to Multiple Doses of Ivermectin” NCT07286604 ↗ “Ivermectin (IVM), a macrocyclic lactone with a wide anti-parasitary spectrum, has shown potent activity against SARS-CoV-2 in vitro.” PMID 34189446 ↗ Jun 2021 “fixed dose combination (FDC) of albendazole (ALB) and ivermectin (IVM) as a single dose to treat Soil-Transmitted Helminths (STH)” NCT06282315 ↗ “Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg) plus Albendazole (ALB) (400 mg)” NCT06070116 ↗ “Ivermectin (IVM) is a broad-spectrum anthelmintic drug used to treat diseases caused by filarial worms” PMID 37262040 ↗ Jun 2023 “Ivermectin (IVM) and albendazole (ALB) are administered in areas where onchocerciasis is co-endemic;” NCT02899936 ↗ |
| Known as | IVR | “Ivermectin (IVR) 200 µg/kg” NCT02845713 ↗ |
| Known as | Mectizan | “Following recommendations 1 dose of 150 µg/kg Ivermectin (Mectizan®) will be administered orally, treatment will be directly observed (DOT).” NCT03052998 ↗2“following the appearance of Ivermectin (Mectizan) on the scene in the late 1980's” NCT03238131 ↗ “Ivermectin (Mectizan) was donated by the Mectizan Donation Program” PMID 37152362 ↗ Apr 2023 |
| Known as | REVECTINA | “containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)” NCT03173742 ↗ |
| Known as | SKLICE | “SKLICE® (ivermectin) lotion, 0.5% (Arbor Pharmaceuticals, LLC)” NCT03301649 ↗ |
| Known as | SoolantraTM | “Ivermectin Cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (Ivermectin) Cream 1% (Galderma)” NCT02840461 ↗ |
| Known as | Stromectol | “Comparative Bioavailability Pilot Study of 3 W0035 Test Oral Suspensions (Ivermectin 1mg/mL) Versus Stromectol® (Ivermectin, 3 mg Tablet)” NCT03717558 ↗2“400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of ivermectin (Stromectol®) at day 0 administered orally” NCT03527732 ↗ “They will have been randomly assigned to the test (Stromectol) or control (placebo) group” NCT03459794 ↗ |
| Action | Inhibit | “Ivermectin was identified as an inhibitor of interaction between the human immunodeficiency virus-1 (HIV-1) integrase protein (IN) and the importin (IMP) α/β1 heterodimer...” NCT04360356 ↗ |
| Modality | Small molecule | “Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.” NCT02046200 ↗ |
| Route | Oral | “received a single oral dose of 2 mg (N = 44), 4 mg (N = 45) or 8 mg (N = 38) moxidectin or 150 µg/kg ivermectin (N = 45) with 18 months follow up” PMID 24968000 ↗ Jun 2014 |